Avid Bioservices Inc (CDMO)

[mojojojo]

I'm not here to defend Garnick's statement, I'm just trying to get to the bottom line of what's relevant. It's possible that he was referring specifically to the endpoint of survival. If he was, I think his statement would be accurate. Either way, it would be nice to get a clarification of it.

Getting back to relevance. This statement, taken by itself, bears no relevance on what bavi did in it's 2nd-line NSCLC trial.

1 of the original 3 avastin ph 2 studies were stat sig
The lucentis ph 2 in AMD was stat sig
xolair ph 2 was stat sig

I don't care what lucentis did in AMD. I don't care what xolair did in asthma. I've looked at avastin and don't recall seeing any phase 2 results as impressive as bavi's 2nd-line NSCLC results. If I had, it would be relevant.

I was looking at this discussion over on the BV board and found this by NP1986. #msg-79465393

We don't yet know that anybody is still alive because of bavituximab. If bavituximab shows a statistically significant overall survival benefit in a large, well-designed phase III trial, then we can be more certain that bavituximab actually increases survival.

So I think he's saying that in most cases the definitive viability of a drug can't be established until the phase 3 results are in and bavi falls into that category. I agree with that. On the other hand, I'm not sure how profitable an investment strategy that's based on this type of analysis would be.

All IMO,

mojo